ReviewInnere Medizin (Heidelberg, Germany)2026
[Anti-inflammatory treatment strategies in coronary heart disease].
Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite advances in lipid-lowering, antithrombotic, and interventional therapies, coronary heart disease (CHD) remains associated with a substantial risk of recurrent cardiovascular events. Inflammation has emerged as a major contributor to this residual risk. Experimental and clinical evidence indicates that inflammatory pathways, particularly activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome and, downstream, the interleukin-1β-interleukin-6-C-reactive protein (CRP) axis, play a key role in atherosclerotic plaque progression and destabilization.
objectivesThis review summarizes the clinical evidence for anti-inflammatory therapies in patients with CHD. CURRENT DATA: The CANTOS trial provided the first evidence that inhibition of interleukin-1β in CHD patients with elevated CRP reduces major adverse cardiovascular events independently of lipid lowering. Low-dose colchicine significantly reduced cardiovascular events in several trials, both early after myocardial infarction and in patients with chronic coronary disease.
conclusionsThese findings establish inflammation as a modifiable therapeutic target in the secondary prevention of CHD and support colchicine as the most advisable anti-inflammatory treatment currently available for CHD.
Indexed as
Identifiers
41811478What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.